slides · global inventory
47 Quick Win Big Bet
Loop collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 9,718
Current window 5,341-5,370
Pages 324
Rows per page 30
Loop
5,341-5,370 of 9,718
40
Uses a four-column layout to categorize value propositions.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
41
PoS stands for Probability of Success. The slide uses a timeline framework to contrast traditional drug development with Absci's approach.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
42
Uses a dot-plot style bar chart to represent revenue over a 25-year period.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
43
Absci | Investor Presentation Deck | 48 slidesAbsci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
13
The slide uses a Gantt-style visualization to show the progress of various drug candidates (SPY001-SPY230).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
14
The slide uses a Gantt-style visualization to show the status of various drug development programs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
15
Includes a KOL quote and specific market share metrics for US/EU regions.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
16
The chart uses a dual-axis approach to imply a safety-efficacy trade-off, positioning vedolizumab as the 'safest' and highly effective.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
17
The slide uses a checkmark/empty circle matrix to highlight competitive differentiation.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
18
The slide uses a central antibody diagram to annotate specific technical improvements over 1st generation mAbs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
19
Includes structural biology visualization and dose-response curves for two different adhesion targets.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
20
The slide demonstrates bio-equivalence in binding affinity to a specific T-cell population.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
21
The chart compares SPY001 against two vedolizumab datasets (internal and Takeda).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
22
Uses YTE modification as a mechanism for half-life extension.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
23
The slide uses a visual timeline/comparison to contrast the competitor's high-frequency, citrate-containing formulation with the company's low-frequency, citrate-free formulation.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
24
The chart compares benchmark induction remission rates with vedolizumab exposure quartiles.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
25
Data from GEMINI 1 study; highlights that higher drug concentration does not necessarily correlate with higher efficacy in maintenance.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
26
The slide uses a standard 2x2 grid for program summary and a simple timeline for catalysts.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
27
Uses historical peer data (Morphic, Prometheus) to project value inflection points for SPY001.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
28
The slide uses a comparison table to establish competitive positioning.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
29
The slide uses qualitative expert feedback to support quantitative preference share data.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
30
The slide uses a table-like layout to represent a drug development pipeline.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
23
The slide uses a donut chart for total cumulative capex and a stacked bar chart to illustrate the shift in product mix over time.Aston Martin Lagonda | Results Presentation Deck | 28 slides · Aston Martin Lagonda
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
10
The slide uses a green sidebar for context and a bar chart for quantitative performance.Crocs | Results Presentation Deck | 40 slides · Crocs
Conference presentation Investor relations Beat · SatisfactionLoop · Quick Win Big Bet1 hit
11
Q2 Highlights slide showing marketing activations and sales rankings.Crocs | Results Presentation Deck | 40 slides · Crocs
Conference presentation Investor relations Beat · SatisfactionLoop · Quick Win Big Bet1 hit
12
The slide highlights strong growth metrics for the HEYDUDE brand under Crocs Inc.Crocs | Results Presentation Deck | 40 slides · Crocs
Conference presentation Investor relations Beat · SatisfactionLoop · Quick Win Big Bet1 hit
08
Essity | Results Presentation Deck | 19 slidesEssity | Results Presentation Deck | 19 slides · Essity
Conference presentation Investor relations Beat · Efficiency ImprovementsLoop · Quick Win Big Bet1 hit
29
The slide uses a stylized molecular or particle-based visual representation, likely related to the drug's mechanism of action.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
15
The slide uses dashed boxes to visually isolate the COVID-19 impacted period (FY 2020-2021).Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Beat · FinancialsLoop · Quick Win Big Bet1 hit
16
2020 data is omitted due to COVID-19.Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Beat · FinancialsLoop · Quick Win Big Bet1 hit